ArticleEMBO molecular medicine2021

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.

Zhang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.